Quick Comparison
1 Ascension Peptides50% OFF—THEPEPTIDECATALOGCopy Yes 10/10 10mg$43.00$4.30/mgView → 2 Ion Peptide15% OFF—thepeptidecatalogCopy 9/10 10mg$35.00$3.50/mgView →20mg$67.00$3.35/mgView → 3 EZ Peptides10% OFF—thepep…
Approved comparison material connected to this topic.
23 total recordsSource comparisons are presented without a generated winner.
1 Ascension Peptides50% OFF—THEPEPTIDECATALOGCopy Yes 10/10 10mg$43.00$4.30/mgView → 2 Ion Peptide15% OFF—thepeptidecatalogCopy 9/10 10mg$35.00$3.50/mgView →20mg$67.00$3.35/mgView → 3 EZ Peptides10% OFF—thepep…
Type I-II (Very Fair) 0.25mg daily, increase to 0.5mg after week 1 4–6 weeks 0.5mg twice weekly 3–4 weeks with minimal UV exposure Slowest responders due to low melanocyte density. Patience and conservative UV…
0.1–0.2mg daily 20–40% 4–6 hours, inconsistent <5% Minimal to none Subtherapeutic for appetite. Insufficient receptor activation for reliable satiety signaling 0.25–0.5mg daily 60–85% 8–12 hours, consistent 10…
Loading Phase 0.25mg Daily for 5–7 days 2–4 hours post-injection MC1R priming, minimal pigmentation, reduced nausea risk Start here. Receptor saturation without off-target effects Escalation Phase 0.5–1.0mg Da…
Most published protocols differentiate between loading phases and maintenance dosing. A loading phase involves daily low-dose administration (0.25–0.5mg) for 3–7 days to gradually upregulate melanocortin recep…
0.25–0.5mg daily Mild increase in sexual desire; noticeable arousal threshold reduction after 3–5 days 3–4 hours / 6 hours Minimal. Mild flushing in 15–20% Lowest dose range tested in Phase II female arousal t…
| Protocol Type | Loading Dose | Duration | Maintenance Dose | UV Exposure Timing | Side Effect Profile | Professional Assessment ||—|—|—|—|—|—|| Conservative (Fitzpatrick I–II) | 0.25mg daily → 0.5mg daily | …
Loading Phase + Maintenance 0.25–0.5mg daily for 5–7 days, then 1–1.5mg as needed Daily loading, then 2–3×/week 15–25% during loading, <10% at maintenance 90–180 minutes post-injection Lowest side effect profi…
Acute administration. Single doses timed 45–120 minutes before desired sexual activity. Relies on plasma peak concentration aligning with the activity window. MT-2 administered subcutaneously reaches Cmax (max…
Conservative (evidence-based) 0.25mg daily × 5–7 days, then 0.5mg daily 10–14 days 15–20% 0.5mg 2×/week Prioritises tolerability; slower onset but higher compliance Moderate (hybrid) 0.5mg daily from day 1 7–1…
0.1–0.25mg daily Minimal appetite reduction; threshold MC4R activation Very low. No visible darkening in most users 20–30% during first week Initial sensitivity testing; pediatric research contexts Subtherapeu…
Loading (Type I–II) 0.25–0.5mg daily 10–14 days Visible tan by day 7–10; moderate depth by day 14 Nausea 15–25%, flushing 10–20%, minimal sexual sides at low dose Best for fair skin. Slow ramp minimises uneven…
| Protocol Type | Dose Range | Administration Timing | Onset Window | Duration of Effect | Receptor Mechanism | Side Effect Profile ||—|—|—|—|—|—|| Acute Single-Dose | 0.5–1mg | 60–90 min pre-activity | 45–120…
Type I (very fair, always burns) 0.25mg daily 14–21 days 0.25–0.5mg 2–3×/week 10 min/session, 2×/week Light tan (2–3 shades darker than baseline) Requires longest titration; MC1R density is lowest, so receptor…
The following table compares Melanotan-2 dosing tiers for erectile function against key efficacy and safety markers based on clinical observations and user-reported data from research contexts. 0.25mg subcutan…
When evaluating Melanotan-2 preparations for research applications, the comparison must focus on verifiable quality markers rather than marketing claims. Here's how research-grade MT-2 compares across the crit…
Before purchasing Melanotan-2, evaluate these criteria across suppliers: documented purity via third-party CoA, synthesis method disclosure (SPPS with Fmoc chemistry is standard), lyophilisation process (pharm…
Choosing research-grade Melanotan-2 means evaluating synthesis method, purity verification, storage conditions, and supplier transparency. The table below compares what separates pharmaceutical-grade MT2 from …
The table below compares synthesis and verification standards across MT-2 quality tiers, showing what differentiates research-grade product from commercial analogues: Research-Grade (Real Peptides Standard) Sm…
Selecting the right Melanotan-2 source for appetite suppression research requires evaluating peptide purity, synthesis method, storage conditions, and third-party verification. The table below compares key qua…